RxDoctor Payments Data

Joshua Jurczak

Nurse Practitioner · Gainesville, FLNPI 1508471616

Payments from drug & device makers

$2,717in general payments, 2019–2025

Across 76 payments — averaging $35.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$633
  • GSK$397
  • Sanofi$386
  • Takeda Pharmaceuticals U.S.A., Inc.$266
  • AbbVie$231
  • Regeneron Healthcare Solutions, Inc.$216
  • plus $588 from 8 others

What the payments were for

  • Food & beverage$2,61796%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,717 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$65,261
Medicare patients
339
Services billed
2,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab22$114,077
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$95,768
Spiriva RespimatTiotropium Bromide25$21,541
Breo ElliptaFluticasone/Vilanterol33$16,204
Advair HfaFluticasone Propion/Salmeterol11$8,531
SymbicortBudesonide/Formoterol Fumarate16$7,024
Ipratropium Bromide146$6,133
Azelastine Hcl132$5,740
Arnuity ElliptaFluticasone Furoate15$5,013
Epinephrine28$4,624
Qvar RedihalerBeclomethasone Dipropionate14$4,489
Wixela InhubFluticasone Propion/Salmeterol27$4,063
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$3,713
Levocetirizine Dihydrochloride219$2,806
Fluticasone Propionate130$2,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$397$116,985162 claims
AstraZenecaSymbicort$633$7,02416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →